An mHealth Intervention to Improve Medication Adherence and Health Outcomes Among Patients With Coronary Heart Disease: Randomized Controlled Trial

Zhao Ni, Bei Wu, Qing Yang, Lijing L Yan, Changqing Liu, Ryan J Shaw, Zhao Ni, Bei Wu, Qing Yang, Lijing L Yan, Changqing Liu, Ryan J Shaw

Abstract

Background: The treatment of many chronic illnesses involves long-term pharmaceutical therapy, but it is an ongoing challenge to find effective ways to improve medication adherence to promote good health outcomes. Cardioprotective medications can prevent the enlargement of harmful clots, cardiovascular symptoms, and poor therapeutic outcomes, such as uncontrolled high blood pressure and hyperlipidemia, for patients with coronary heart disease. Poor adherence to cardioprotective medications, however, has been reported as a global health concern among patients with coronary heart disease, and it is particularly a concern in China.

Objective: This study aimed to evaluate the efficacy of a mobile health (mHealth) intervention using 2 mobile apps to improve medication adherence and health outcomes.

Methods: A randomized, placebo-controlled, 2-arm parallel study was conducted in a major university-affiliated medical center located in Chengdu, China. Participants were recruited by flyers and health care provider referrals. Each participant was observed for 90 days, including a 60-day period of mHealth intervention and a 30-day period of nonintervention follow-up. The study coordinator used WeChat and Message Express to send educational materials and reminders to take medication, respectively. Participants used WeChat to receive both the educational materials and reminders. Participants in the control group only received educational materials. This study received ethics approval from the Duke Health Institutional Review Board (Pro00073395) on May 5, 2018, and was approved by West China Hospital (20170331180037). Recruitment began on May 20, 2018. The pilot phase of this study was registered on June 8, 2016, and the current, larger-scale study was retrospectively registered on January 11, 2021 (ClinicalTrials.gov).

Results: We recruited 230 patients with coronary heart disease. Of these patients, 196 completed the baseline survey and received the intervention. The majority of participants were married (181/196, 92.4%), male (157/196, 80.1%), and lived in urban China (161/196, 82.1%). Participants' average age was 61 years, and half were retired (103/191, 53.9%). More than half the participants (121/196, 61.7%) were prescribed at least 5 medications. The mean decrease in medication nonadherence score was statistically significant at both 60 days (t179=2.04, P=.04) and 90 days (t155=3.48, P<.001). Systolic blood pressure and diastolic blood pressure decreased in the experimental group but increased in the control group. The mean decrease in diastolic blood pressure was statistically significant at both 60 days (t160=2.07, P=.04) and 90 days (t164=2.21, P=.03). The mean decrease in systolic blood pressure was significantly different in the groups at 90 days (t165=3.12, P=.002).

Conclusions: The proposed mHealth intervention can improve medication adherence and health outcomes, including systolic blood pressure and diastolic blood pressure.

Trial registration: ClinicalTrials.gov NCT02793830; https://ichgcp.net/clinical-trials-registry/NCT02793830 and ClinicalTrials.gov NCT04703439; https://ichgcp.net/clinical-trials-registry/NCT04703439.

Keywords: China; blood pressure; coronary disease; mHealth; medication adherence; randomized controlled trial.

Conflict of interest statement

Conflicts of Interest: None declared.

©Zhao Ni, Bei Wu, Qing Yang, Lijing L Yan, Changqing Liu, Ryan J Shaw. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 09.03.2022.

Figures

Figure 1
Figure 1
Brief description of the 2 apps.
Figure 2
Figure 2
CONSORT (Consolidated Standards of Reporting Trials) flow diagram.
Figure 3
Figure 3
Comparison of changes in medication nonadherence score between groups (SE 2).
Figure 4
Figure 4
Comparison of changes in heart rate between groups (SE 2).
Figure 5
Figure 5
Comparison of changes in systolic blood pressure between groups (SE 2).
Figure 6
Figure 6
Comparison of changes in diastolic blood pressure between groups (SE 2).

References

    1. What is Cardiovascular Disease? American Heart Association. 2017. May 31, [2019-02-20]. .
    1. The top 10 causes of death. World Health Organization. 2020. Dec 09, [2021-02-01]. .
    1. Wilson PWF, Douglas PS. Epidemiology of coronary heart disease. UpToDate. 2017. [2022-03-04]. .
    1. Bowry ADK, Lewey J, Dugani SB, Choudhry NK. The Burden of Cardiovascular Disease in Low- and Middle-Income Countries: Epidemiology and Management. Can J Cardiol. 2015 Sep;31(9):1151–9. doi: 10.1016/j.cjca.2015.06.028.S0828-282X(15)00507-3
    1. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol. 2010 Feb;35(2):72–115. doi: 10.1016/j.cpcardiol.2009.10.002. S0146-2806(09)00127-3
    1. The Global Burden of Disease. World Health Organization. 2004. [2019-11-20]. .
    1. China remains largest developing country: Economist. China Daily. 2018. [2019-02-10]. .
    1. China Overview. The World Bank. [2019-02-10]. .
    1. China: WHO statistical profile. World Health Organization. 2015. [2019-01-22]. .
    1. Zhang X, Lu ZL, Liu L. Coronary heart disease in China. Heart. 2008 Sep;94(9):1126–31. doi: 10.1136/hrt.2007.132423.94/9/1126
    1. Le C, Fang Y, Linxiong W, Shulan Z, Golden AR. Economic burden and cost determinants of coronary heart disease in rural southwest China: a multilevel analysis. Public Health. 2015 Jan;129(1):68–73. doi: 10.1016/j.puhe.2014.11.002.S0033-3506(14)00291-1
    1. Chen W, Gao R, Liu L, Zhu M, Wang W, Wang Y, Wu Z, Li H, Gu D, Yang Y, Zheng Z, Jiang L, Hu S. China cardiovascular diseases report 2015: a summary. J Geriatr Cardiol. 2017 Jan;14(1):1–10. doi: 10.11909/j.issn.1671-5411.2017.01.012. jgc-14-01-001
    1. Conary Heart Disease - Treatment. National Heart, Lung, and Blood Institute. [2019-02-01]. .
    1. Adherence to long-term therapies. World Health Organization. 2003. [2020-02-26]. .
    1. Hamm Christian W, Bassand Jean-Pierre, Agewall Stefan, Bax Jeroen, Boersma Eric, Bueno Hector, Caso Pio, Dudek Dariusz, Gielen Stephan, Huber Kurt, Ohman Magnus, Petrie Mark C, Sonntag Frank, Uva Miguel Sousa, Storey Robert F, Wijns William, Zahger Doron, ESC Committee for Practice Guidelines ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J. 2011 Dec;32(23):2999–3054. doi: 10.1093/eurheartj/ehr236.ehr236
    1. Zhang H, Yuan X, Zhang H, Chen S, Zhao Y, Hua K, Rao C, Wang W, Sun H, Hu S, Zheng Z. Efficacy of Long-Term β-Blocker Therapy for Secondary Prevention of Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery. Circulation. 2015 Jun 23;131(25):2194–201. doi: 10.1161/CIRCULATIONAHA.114.014209. CIRCULATIONAHA.114.014209
    1. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009 Jun 16;119(23):3028–35. doi: 10.1161/CIRCULATIONAHA.108.768986.119/23/3028
    1. Jiang J, Hong T, Yu R, Zhang Y, Liu Z, Huo Y. Knowledge of secondary prevention guidelines for coronary heart disease: results from a physicians' survey in China. Eur J Prev Cardiol. 2012 Oct;19(5):991–8. doi: 10.1177/1741826711421299.1741826711421299
    1. Ni Z, Liu C, Wu B, Yang Q, Douglas C, Shaw RJ. An mHealth intervention to improve medication adherence among patients with coronary heart disease in China: Development of an intervention. International Journal of Nursing Sciences. 2018 Oct;5(4):322–330. doi: 10.1016/j.ijnss.2018.09.003.
    1. Iuga Aurel O, McGuire Maura J. Adherence and health care costs. Risk Manag Healthc Policy. 2014;7:35–44. doi: 10.2147/RMHP.S19801. doi: 10.2147/RMHP.S19801.rmhp-7-035
    1. Ni Z, Dardas L, Wu B, Shaw R. Cardioprotective medication adherence among patients with coronary heart disease in China: a systematic review. Heart Asia. 2019;11(2):e011173. doi: 10.1136/heartasia-2018-011173. heartasia-2018-011173
    1. Ding R, Ma C, Chen H, Wu Y, Yang X, Hua Q, Li R, Ren W, Wang M, Xiang X, Du X, Pi L, Hu D. [Control rate of increased low-density lipoprotein cholesterol levels in cardiology outpatients with coronary heart disease in Beijing] Zhonghua Xin Xue Guan Bing Za Zhi. 2013 Mar;41(3):251–5.
    1. Zhao S, Zhao H, Wang L, Du S, Qin Y. Education is critical for medication adherence in patients with coronary heart disease. Acta Cardiol. 2015 Apr;70(2):197–204. doi: 10.1080/ac.70.2.3073511.
    1. Wang H, Zhang D, Hou Z, Yan F, Hou Z. Association between social health insurance and choice of hospitals among internal migrants in China: a national cross-sectional study. BMJ Open. 2018 Feb 10;8(2):e018440. doi: 10.1136/bmjopen-2017-018440. bmjopen-2017-018440
    1. Meng Q, Yang H, Chen W, Sun Q, Liu X. People's Republic of China Health System Review. 2019. [2019-11-18]. .
    1. Ventola CL. Mobile devices and apps for health care professionals: uses and benefits. P T. 2014 May;39(5):356–64.
    1. Boulos MNK, Brewer AC, Karimkhani C, Buller DB, Dellavalle RP. Mobile medical and health apps: state of the art, concerns, regulatory control and certification. Online J Public Health Inform. 2014;5(3):229. doi: 10.5210/ojphi.v5i3.4814. ojphi-05-e229
    1. mHealth for development: the opportunity of mobile technology for healthcare in the developing world. Vital Wave Consulting. [2019-11-20]. .
    1. He Y. China's mobile users hit 1.3 billion in 2015. China Daily; 2015. [2019-01-22]. .
    1. Statistical Report on Internet Development in China. China Internet Network Information Center. 2018. [2019-01-22]. .
    1. Dorje T, Zhao G, Scheer Anna, Tsokey Lhamo, Wang Jing, Chen Yaolin, Tso Khandro, Tan B-k, Ge Junbo, Maiorana Andrew. SMARTphone and social media-based Cardiac Rehabilitation and Secondary Prevention (SMART-CR/SP) for patients with coronary heart disease in China: a randomised controlled trial protocol. BMJ Open. 2018 Jun 30;8(6):e021908. doi: 10.1136/bmjopen-2018-021908. bmjopen-2018-021908
    1. Dorje T, Zhao G, Tso K, Wang J, Chen Y, Tsokey L, Tan B, Scheer A, Jacques A, Li Z, Wang R, Chow CK, Ge J, Maiorana A. Smartphone and social media-based cardiac rehabilitation and secondary prevention in China (SMART-CR/SP): a parallel-group, single-blind, randomised controlled trial. Lancet Digit Health. 2019 Nov;1(7):e363–e374. doi: 10.1016/S2589-7500(19)30151-7. S2589-7500(19)30151-7
    1. Li T, Ding W, Li X, Lin A. Mobile health technology (WeChat) for the hierarchical management of community hypertension: protocol for a cluster randomized controlled trial. Patient Prefer Adherence. 2019;13:1339–1352. doi: 10.2147/PPA.S215719. doi: 10.2147/PPA.S215719.215719
    1. Li X, Li T, Chen J, Xie Y, An X, Lv Y, Lin A. A WeChat-Based Self-Management Intervention for Community Middle-Aged and Elderly Adults with Hypertension in Guangzhou, China: A Cluster-Randomized Controlled Trial. Int J Environ Res Public Health. 2019 Oct 23;16(21):40–58. doi: 10.3390/ijerph16214058. ijerph16214058
    1. Park LG, Beatty A, Stafford Z, Whooley MA. Mobile Phone Interventions for the Secondary Prevention of Cardiovascular Disease. Prog Cardiovasc Dis. 2016;58(6):639–50. doi: 10.1016/j.pcad.2016.03.002.S0033-0620(16)30020-2
    1. Li X, Xu Z, Tang N, Ye C, Zhu X, Zhou T, Zhao Z. Effect of intervention using a messaging app on compliance and duration of treatment in orthodontic patients. Clin Oral Investig. 2016 Nov;20(8):1849–1859. doi: 10.1007/s00784-015-1662-6.10.1007/s00784-015-1662-6
    1. Luo L, Luo L, Zhang X, He X. Hospital daily outpatient visits forecasting using a combinatorial model based on ARIMA and SES models. BMC Health Serv Res. 2017 Jul 10;17(1):469. doi: 10.1186/s12913-017-2407-9. 10.1186/s12913-017-2407-9
    1. Jacob C. Statistical power analysis for the behavioural sciences (second edition) Lawrence Earlbaum Associates: Hillsdale, NJ; 1988.
    1. Cunningham JB, Gardner E. Power, effect and sample size using GPower: practical issues for researchers and members of research ethics committees. Evidence Based Midwifery. 2007;5(4):132–136.
    1. World Health Organization 事实档案 [Facts in pictures] [2017-01-01]. .
    1. World Health Organization 心血管疾病 [Cardiovascular diseases] [2017-01-01]. .
    1. Voils CI, Maciejewski ML, Hoyle RH, Reeve BB, Gallagher P, Bryson CL, Yancy WS. Initial validation of a self-report measure of the extent of and reasons for medication nonadherence. Med Care. 2012 Dec;50(12):1013–9. doi: 10.1097/MLR.0b013e318269e121.
    1. Liu L, Writing Group of 2010 Chinese Guidelines for the Management of Hypertension [2010 Chinese guidelines for the management of hypertension] Zhonghua Xin Xue Guan Bing Za Zhi. 2011 Jul;39(7):579–615.
    1. Schulz KF, Altman DG, Moher D, Fergusson D. CONSORT 2010 changes and testing blindness in RCTs. Lancet. 2010 Apr 03;375(9721):1144–6. doi: 10.1016/S0140-6736(10)60413-8.S0140-6736(10)60413-8
    1. Harsha DW, Bray GA. Weight loss and blood pressure control (Pro) Hypertension. 2008 Jun;51(6):1420–5. doi: 10.1161/HYPERTENSIONAHA.107.094011.HYPERTENSIONAHA.107.094011
    1. Seimon RV, Espinoza D, Finer N, James WPT, Legler UF, Coutinho W, Sharma AM, Van Gaal L, Maggioni AP, Sweeting A, Torp-Pedersen C, Gebski V, Caterson ID. Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. Int J Obes (Lond) 2015 May;39(5):849–57. doi: 10.1038/ijo.2014.211.ijo2014211
    1. Maranon R, Reckelhoff JF. Sex and gender differences in control of blood pressure. Clin Sci (Lond) 2013 Oct;125(7):311–8. doi: 10.1042/CS20130140. CS20130140
    1. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001 May;37(5):1199–208. doi: 10.1161/01.hyp.37.5.1199.
    1. Buford TW. Hypertension and aging. Ageing Res Rev. 2016 Mar;26:96–111. doi: 10.1016/j.arr.2016.01.007. S1568-1637(16)30007-1
    1. Mosca L, Barrett-Connor E, Wenger Nanette Kass. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation. 2011 Nov 08;124(19):2145–54. doi: 10.1161/CIRCULATIONAHA.110.968792. 124/19/2145
    1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J, American Heart Association Statistics CommitteeStroke Statistics Subcommittee Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011 Feb 01;123(4):e18–e209. doi: 10.1161/CIR.0b013e3182009701. CIR.0b013e3182009701
    1. Bi Y, Gao R, Patel A, Su S, Gao W, Hu D, Huang D, Kong L, Qi W, Wu Y, Yang Y, Turnbull F, CPACS Investigators Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study. Am Heart J. 2009 Mar;157(3):509–516.e1. doi: 10.1016/j.ahj.2008.09.026.S0002-8703(08)00908-3
    1. Xie X, Liu P, Zheng Y, Zhou W, Zou J, Wang X, Wang L, Guo T, Ma X, He Y, Chen Y. Equity of health resource distribution in China during 2009–15: an analysis of cross-sectional nationwide data. The Lancet. 2017 Dec;390:S6. doi: 10.1016/s0140-6736(17)33144-6.
    1. Wang H, Xu T, Xu J. Factors contributing to high costs and inequality in China's health care system. JAMA. 2007 Oct 24;298(16):1928–30. doi: 10.1001/jama.298.16.1928.298/16/1928
    1. Li X, Huang J, Zhang H. An analysis of hospital preparedness capacity for public health emergency in four regions of China: Beijing, Shandong, Guangxi, and Hainan. BMC Public Health. 2008 Sep 20;8:319. doi: 10.1186/1471-2458-8-319. 1471-2458-8-319

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere